Search

Somatuline Autogel

Somatuline Autogel

lanreotide

Manufacturer:

Ipsen Pharma

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Lanreotide
Indications/Uses
Acromegaly when secretions of growth hormone & insulin-like growth factor-1 remain abnormal after surgery &/or RT, clinical symptoms associated w/ acromegaly & neuroendocrine (particularly carcinoid) tumours. 120 mg: Grade 1 & subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded in adult patients w/ unresectable locally advanced or metastatic disease.
Click to view Somatuline Autogel detailed prescribing information
Dosage/Direction for Use
Acromegaly & carcinoid tumours Initially 60-120 mg deep SC inj every 28 days, may be increased/decreased depending on patient's response. GEP-NETs 120 mg as single deep SC inj every 28 days continued as long as needed.
Click to view Somatuline Autogel detailed prescribing information
Overdosage
View Somatuline Autogel overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to lanreotide, somatostatin or related peptides. Lactation.
Click to view Somatuline Autogel detailed prescribing information
Special Precautions
Patients w/ bradycardia, preexisting cardiac disorders; steatorrhoea. Monitor blood glucose levels; pituitary tumour vol in patients w/ adenomas. Perform gallbladder echography prior to, during & every 6 mth of treatment; thyroid function test during therapy. May affect ability to drive & use machines. May affect female fertility. Avoid use during pregnancy. Not to be used during lactation. Childn & adolescents.
Click to view Somatuline Autogel detailed prescribing information
Adverse Reactions
GI disorders eg, diarrhoea, loose stools, abdominal pain; cholelithiasis; inj site pain, nodule & induration. Hypo- & hyperglycaemia, decreased appetite, DM; dizziness, headache, lethargy; sinus bradycardia; nausea, vomiting, constipation, flatulence, abdominal distension & discomfort, dyspepsia, steatorrhoea; biliary dilatation; musculoskeletal pain, myalgia; alopecia, hypotrichosis; asthenia, fatigue, inj site mass & pruritus; increased ALAT, glycosylated Hb, blood bilirubin & glucose, abnormal ASAT & ALAT, decreased wt & pancreatic enzymes.
Click to view Somatuline Autogel detailed prescribing information
Drug Interactions
Decreased blood levels of cyclosporin. Risk of hyper- or hypoglycaemia w/ insulin, glitazones, repaglinide, sulphonylureas. Slight heart rate reduction w/ bradycardia-inducing drugs eg, β-blockers. Decreased metabolic clearance of CYP3A4-metabolized drugs & drugs w/ low therapeutic index eg, quinidine.
Click to view Somatuline Autogel detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Somatuline Autogel detailed prescribing information
Storage
View Somatuline Autogel storage conditions for details to ensure optimal shelf-life.
Description
View Somatuline Autogel description for details of the chemical structure and excipients (inactive components).
Action
View Somatuline Autogel mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Trophic Hormones & Related Synthetic Drugs
ATC Classification
H01CB03 - lanreotide ; Belongs to the class of antigrowth hormone. Used in hypothalamic hormone preparations.
Presentation/Packing
Form
Somatuline Autogel PR soln for inj (pre-filled syringe) 120 mg
Packing/Price
0.5 mL x 1's
Form
Somatuline Autogel PR soln for inj (pre-filled syringe) 60 mg
Packing/Price
0.5 mL x 1's
Form
Somatuline Autogel PR soln for inj (pre-filled syringe) 90 mg
Packing/Price
0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in